Concepedia

Constance King

CK

Statistics

Publications

4

Citations

409

H-Index

4

Active since

2004

Affiliations

Eli Lilly (United States)(Current)

Constance King is an author at Eli Lilly (United States) specializing in chk1 signaling, tyrosine kinase inhibitors, and pharmacology.

Publications per year

2004–2015

4

Publications

4

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

Constance King, H. Bruce Diaz, Samuel McNeely et al. · Molecular Cancer Therapeutics · 2015 · 189 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

Constance King, Henry Diaz, Darlene Barnard et al. · Investigational New Drugs · 2013 · 111 citations

Medicine, Medicinal Chemistry, Pharmacology +11

Water management along the flow channels of PEM fuel cells

Jung S. Yi, Jangsik Yang, Constance King · AIChE Journal · 2004 · 81 citations

Engineering, Chemical Engineering, Water Resources Management +17

LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models

Darlene Barnard, H. Bruce Diaz, Teresa F. Burke et al. · Investigational New Drugs · 2015 · 28 citations

Medicine, Oncology, Pharmacology +12

1–4 of 4